Heron's Sustol Faces Competition With Narrower Label Than Expected
Executive Summary
Heron Therapeutics gained approval of its chemotherapy-induced nausea and vomiting drug Sustol (granisetron), but the company faces stiff competition and postmarketing requirements. Analysts, nonetheless, think the product has a bright future on the US market.
You may also be interested in...
Finance Watch: The Year's Biggest IPO And A Post-ASH Offering Splash
Public Company Edition: Denali launched this year's largest biopharma IPO. Also, Valeant sold notes to retire older debt, while bluebird, Blueprint and others capitalized on data presented at ASH.
Keeping Track: Opana ER Abuse Deterrence Claim Withdrawn; Third Neulasta Biosimilar Submitted; Keytruda Cleared In Head And Neck Cancer
The latest drug development news and highlights from our FDA Performance Tracker.
Heron hammered over Sustol NDA resubmission delay
Investors hammered Heron Therapeutics on 27 January, with shares tumbling as low as 19.2% in morning trading, after the company revealed it was forced to delay by at least three months its resubmission to the FDA of the firm’s new drug application (NDA) for its experimental chemotherapy-induced nausea and vomiting (CINV) drug Sustol (APF530).